Ani Pharmaceuticals Stock Fundamentals
| ANIP Stock | USD 68.36 1.19 1.77% |
ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.
At this time, ANI Pharmaceuticals' Research Development is relatively stable compared to the past year. As of 03/28/2025, EBITDA is likely to grow to about 66.3 M, while Income Tax Expense is likely to drop (3.9 M).
ANI | Select Account or Indicator |
ANI Pharmaceuticals Company Current Valuation Analysis
ANI Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ANI Pharmaceuticals Current Valuation | 1.96 B |
Most of ANI Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ANI Pharmaceuticals has a Current Valuation of 1.96 B. This is 86.36% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 88.21% higher than that of the company.
ANI Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ANI Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare ANI Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ANI Pharmaceuticals competition to find correlations between indicators driving ANI Pharmaceuticals's intrinsic value. More Info.ANI Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, ANI Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ANI Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ANI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is currently under evaluation in current valuation category among its peers.
ANI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ANI Fundamentals
| Return On Equity | -0.0418 | ||||
| Return On Asset | 0.0084 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 21.76 M | ||||
| Shares Owned By Insiders | 11.22 % | ||||
| Shares Owned By Institutions | 97.41 % | ||||
| Number Of Shares Shorted | 2.56 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 2.42 X | ||||
| Revenue | 614.38 M | ||||
| Gross Profit | 364.17 M | ||||
| EBITDA | 63.12 M | ||||
| Net Income | (18.52 M) | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 314.98 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.54 X | ||||
| Cash Flow From Operations | 64.02 M | ||||
| Short Ratio | 8.01 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Price To Earnings To Growth | 1.06 X | ||||
| Target Price | 81.5 | ||||
| Number Of Employees | 897 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 1.49 B | ||||
| Total Asset | 1.28 B | ||||
| Retained Earnings | (100.28 M) | ||||
| Working Capital | 334 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
| Net Asset | 1.28 B |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 37.4 M | 39.2 M | |
| Total Revenue | 614.4 M | 645.1 M | |
| Cost Of Revenue | 250.2 M | 262.7 M | |
| Stock Based Compensation To Revenue | 0.05 | 0.05 | |
| Sales General And Administrative To Revenue | 0.25 | 0.24 | |
| Research And Ddevelopement To Revenue | 0.07 | 0.07 | |
| Capex To Revenue | 0.04 | 0.04 | |
| Revenue Per Share | 31.80 | 33.39 |
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.